A citation-based method for searching scientific literature

H Taniguchi, M Ebina, Y Kondoh, T Ogura, A Azuma, M Suga, Y Taguchi, H Takahashi, K Nakata, A Sato, M Takeuchi, G Raghu, S Kudoh, T Nukiwa. Eur Respir J 2010
Times Cited: 630







List of co-cited articles
670 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Talmadge E King, Williamson Z Bradford, Socorro Castro-Bernardini, Elizabeth A Fagan, Ian Glaspole, Marilyn K Glassberg, Eduard Gorina, Peter M Hopkins, David Kardatzke, Lisa Lancaster,[...]. N Engl J Med 2014
58

Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomised trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Marilyn K Glassberg, David Kardatzke, Talmadge E King, Lisa Lancaster, Steven A Sahn, Javier Szwarcberg,[...]. Lancet 2011
57

Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis.
Luca Richeldi, Roland M du Bois, Ganesh Raghu, Arata Azuma, Kevin K Brown, Ulrich Costabel, Vincent Cottin, Kevin R Flaherty, David M Hansell, Yoshikazu Inoue,[...]. N Engl J Med 2014
43

An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management.
Ganesh Raghu, Harold R Collard, Jim J Egan, Fernando J Martinez, Juergen Behr, Kevin K Brown, Thomas V Colby, Jean-François Cordier, Kevin R Flaherty, Joseph A Lasky,[...]. Am J Respir Crit Care Med 2011
39

Double-blind, placebo-controlled trial of pirfenidone in patients with idiopathic pulmonary fibrosis.
Arata Azuma, Toshihiro Nukiwa, Eiyasu Tsuboi, Moritaka Suga, Shosaku Abe, Koichiro Nakata, Yoshio Taguchi, Sonoko Nagai, Harumi Itoh, Motoharu Ohi,[...]. Am J Respir Crit Care Med 2005
631
30

Diagnosis of Idiopathic Pulmonary Fibrosis. An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline.
Ganesh Raghu, Martine Remy-Jardin, Jeffrey L Myers, Luca Richeldi, Christopher J Ryerson, David J Lederer, Juergen Behr, Vincent Cottin, Sonye K Danoff, Ferran Morell,[...]. Am J Respir Crit Care Med 2018
22

An Official ATS/ERS/JRS/ALAT Clinical Practice Guideline: Treatment of Idiopathic Pulmonary Fibrosis. An Update of the 2011 Clinical Practice Guideline.
Ganesh Raghu, Bram Rochwerg, Yuan Zhang, Carlos A Cuello Garcia, Arata Azuma, Juergen Behr, Jan L Brozek, Harold R Collard, William Cunningham, Sakae Homma,[...]. Am J Respir Crit Care Med 2015
22

Acute Exacerbation of Idiopathic Pulmonary Fibrosis. An International Working Group Report.
Harold R Collard, Christopher J Ryerson, Tamera J Corte, Gisli Jenkins, Yasuhiro Kondoh, David J Lederer, Joyce S Lee, Toby M Maher, Athol U Wells, Katerina M Antoniou,[...]. Am J Respir Crit Care Med 2016
599
21

Efficacy of a tyrosine kinase inhibitor in idiopathic pulmonary fibrosis.
Luca Richeldi, Ulrich Costabel, Moises Selman, Dong Soon Kim, David M Hansell, Andrew G Nicholson, Kevin K Brown, Kevin R Flaherty, Paul W Noble, Ganesh Raghu,[...]. N Engl J Med 2011
669
20

An official American Thoracic Society/European Respiratory Society statement: Update of the international multidisciplinary classification of the idiopathic interstitial pneumonias.
William D Travis, Ulrich Costabel, David M Hansell, Talmadge E King, David A Lynch, Andrew G Nicholson, Christopher J Ryerson, Jay H Ryu, Moisés Selman, Athol U Wells,[...]. Am J Respir Crit Care Med 2013
18

Idiopathic Pulmonary Fibrosis.
David J Lederer, Fernando J Martinez. N Engl J Med 2018
575
17

Prednisone, azathioprine, and N-acetylcysteine for pulmonary fibrosis.
Ganesh Raghu, Kevin J Anstrom, Talmadge E King, Joseph A Lasky, Fernando J Martinez. N Engl J Med 2012
932
16

Idiopathic pulmonary fibrosis.
Luca Richeldi, Harold R Collard, Mark G Jones. Lancet 2017
594
16

Pirfenidone for idiopathic pulmonary fibrosis: analysis of pooled data from three multinational phase 3 trials.
Paul W Noble, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Elizabeth A Fagan, Robert S Fishman, Ian Glaspole, Marilyn K Glassberg, Lisa Lancaster,[...]. Eur Respir J 2016
229
14

Clinical course and prediction of survival in idiopathic pulmonary fibrosis.
Brett Ley, Harold R Collard, Talmadge E King. Am J Respir Crit Care Med 2011
930
14

Nintedanib in Progressive Fibrosing Interstitial Lung Diseases.
Kevin R Flaherty, Athol U Wells, Vincent Cottin, Anand Devaraj, Simon L F Walsh, Yoshikazu Inoue, Luca Richeldi, Martin Kolb, Kay Tetzlaff, Susanne Stowasser,[...]. N Engl J Med 2019
549
14

Nintedanib for Systemic Sclerosis-Associated Interstitial Lung Disease.
Oliver Distler, Kristin B Highland, Martina Gahlemann, Arata Azuma, Aryeh Fischer, Maureen D Mayes, Ganesh Raghu, Wiebke Sauter, Mannaig Girard, Margarida Alves,[...]. N Engl J Med 2019
483
13

Pirfenidone in patients with unclassifiable progressive fibrosing interstitial lung disease: a double-blind, randomised, placebo-controlled, phase 2 trial.
Toby M Maher, Tamera J Corte, Aryeh Fischer, Michael Kreuter, David J Lederer, Maria Molina-Molina, Judit Axmann, Klaus-Uwe Kirchgaessler, Katerina Samara, Frank Gilberg,[...]. Lancet Respir Med 2020
201
13

Antifibrotic action of pirfenidone and prednisolone: different effects on pulmonary cytokines and growth factors in bleomycin-induced murine pulmonary fibrosis.
Hisashi Oku, Toshikatsu Shimizu, Tomoji Kawabata, Morio Nagira, Ichiro Hikita, Azumi Ueyama, Shuuichi Matsushima, Mikinori Torii, Akinori Arimura. Eur J Pharmacol 2008
275
12

Effect of pirfenidone on mortality: pooled analyses and meta-analyses of clinical trials in idiopathic pulmonary fibrosis.
Steven D Nathan, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Ian Glaspole, Marilyn K Glassberg, David R Kardatzke, Monica Daigl, Klaus-Uwe Kirchgaessler, Lisa H Lancaster,[...]. Lancet Respir Med 2017
158
12

Mode of action of nintedanib in the treatment of idiopathic pulmonary fibrosis.
Lutz Wollin, Eva Wex, Alexander Pautsch, Gisela Schnapp, Katrin E Hostettler, Susanne Stowasser, Martin Kolb. Eur Respir J 2015
393
12

Nintedanib with Add-on Pirfenidone in Idiopathic Pulmonary Fibrosis. Results of the INJOURNEY Trial.
Carlo Vancheri, Michael Kreuter, Luca Richeldi, Christopher J Ryerson, Dominique Valeyre, Jan C Grutters, Sabrina Wiebe, Wibke Stansen, Manuel Quaresma, Susanne Stowasser,[...]. Am J Respir Crit Care Med 2018
113
12

Epidemiologic survey of Japanese patients with idiopathic pulmonary fibrosis and investigation of ethnic differences.
Motoki Natsuizaka, Hirofumi Chiba, Koji Kuronuma, Mitsuo Otsuka, Kazumi Kudo, Mitsuru Mori, Masashi Bando, Yukihiko Sugiyama, Hiroki Takahashi. Am J Respir Crit Care Med 2014
241
11

Antifibrotic activities of pirfenidone in animal models.
C J Schaefer, D W Ruhrmund, L Pan, S D Seiwert, K Kossen. Eur Respir Rev 2011
263
11

An Open-Label Study of the Long-Term Safety of Pirfenidone in Patients with Idiopathic Pulmonary Fibrosis (RECAP).
Ulrich Costabel, Carlo Albera, Lisa H Lancaster, Chin-Yu Lin, Philip Hormel, Henry N Hulter, Paul W Noble. Respiration 2017
76
14

An Open-label, Phase II Study of the Safety and Tolerability of Pirfenidone in Patients with Scleroderma-associated Interstitial Lung Disease: the LOTUSS Trial.
Dinesh Khanna, Carlo Albera, Aryeh Fischer, Nader Khalidi, Ganesh Raghu, Lorinda Chung, Dan Chen, Elena Schiopu, Margit Tagliaferri, James R Seibold,[...]. J Rheumatol 2016
142
11

Pirfenidone Reduces Respiratory-related Hospitalizations in Idiopathic Pulmonary Fibrosis.
Brett Ley, Jeffrey Swigris, Bann-Mo Day, John L Stauffer, Karina Raimundo, Willis Chou, Harold R Collard. Am J Respir Crit Care Med 2017
91
10

Pirfenidone improves survival in IPF: results from a real-life study.
George A Margaritopoulos, Athina Trachalaki, Athol U Wells, Eirini Vasarmidi, Eleni Bibaki, George Papastratigakis, Stathis Detorakis, Nikos Tzanakis, Katerina M Antoniou. BMC Pulm Med 2018
45
22

Effect of pirfenidone on lung function decline and survival: 5-yr experience from a real-life IPF cohort from the Czech EMPIRE registry.
Monika Zurkova, Eva Kriegova, Vitezslav Kolek, Vladimira Lostakova, Martina Sterclova, Vladimir Bartos, Martina Doubkova, Ilona Binkova, Michal Svoboda, Jana Strenkova,[...]. Respir Res 2019
44
22

Antifibrotic and anti-inflammatory activity of the tyrosine kinase inhibitor nintedanib in experimental models of lung fibrosis.
Lutz Wollin, Isabelle Maillet, Valérie Quesniaux, Alexander Holweg, Bernhard Ryffel. J Pharmacol Exp Ther 2014
328
10

Acute exacerbation of idiopathic pulmonary fibrosis: incidence, risk factors and outcome.
J W Song, S-B Hong, C-M Lim, Y Koh, D S Kim. Eur Respir J 2011
448
9

Pirfenidone safety and adverse event management in idiopathic pulmonary fibrosis.
Lisa H Lancaster, Joao A de Andrade, Joseph D Zibrak, Maria L Padilla, Carlo Albera, Steven D Nathan, Marlies S Wijsenbeek, John L Stauffer, Klaus-Uwe Kirchgaessler, Ulrich Costabel. Eur Respir Rev 2017
75
12

Nintedanib plus Sildenafil in Patients with Idiopathic Pulmonary Fibrosis.
Martin Kolb, Ganesh Raghu, Athol U Wells, Jürgen Behr, Luca Richeldi, Birgit Schinzel, Manuel Quaresma, Susanne Stowasser, Fernando J Martinez. N Engl J Med 2018
117
9

Effect of pirfenidone on proliferation, TGF-β-induced myofibroblast differentiation and fibrogenic activity of primary human lung fibroblasts.
Enrico Conte, Elisa Gili, Evelina Fagone, Mary Fruciano, Maria Iemmolo, Carlo Vancheri. Eur J Pharm Sci 2014
185
9

Nintedanib in patients with progressive fibrosing interstitial lung diseases-subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial.
Athol U Wells, Kevin R Flaherty, Kevin K Brown, Yoshikazu Inoue, Anand Devaraj, Luca Richeldi, Teng Moua, Bruno Crestani, Wim A Wuyts, Susanne Stowasser,[...]. Lancet Respir Med 2020
148
9

Randomized trial of acetylcysteine in idiopathic pulmonary fibrosis.
Fernando J Martinez, Joao A de Andrade, Kevin J Anstrom, Talmadge E King, Ganesh Raghu. N Engl J Med 2014
303
8

A Novel Antifibrotic Mechanism of Nintedanib and Pirfenidone. Inhibition of Collagen Fibril Assembly.
Larissa Knüppel, Yoshihiro Ishikawa, Michaela Aichler, Katharina Heinzelmann, Rudolf Hatz, Jürgen Behr, Axel Walch, Hans Peter Bächinger, Oliver Eickelberg, Claudia A Staab-Weijnitz. Am J Respir Cell Mol Biol 2017
74
10

Pirfenidone in patients with idiopathic pulmonary fibrosis and more advanced lung function impairment.
Steven D Nathan, Ulrich Costabel, Carlo Albera, Jürgen Behr, Wim A Wuyts, Klaus-Uwe Kirchgaessler, John L Stauffer, Elizabeth Morgenthien, Willis Chou, Susan L Limb,[...]. Respir Med 2019
31
25

Long-term safety and tolerability of nintedanib in patients with idiopathic pulmonary fibrosis: results from the open-label extension study, INPULSIS-ON.
Bruno Crestani, John T Huggins, Mitchell Kaye, Ulrich Costabel, Ian Glaspole, Takashi Ogura, Jin Woo Song, Wibke Stansen, Manuel Quaresma, Susanne Stowasser,[...]. Lancet Respir Med 2019
88
9

BIBF 1120: triple angiokinase inhibitor with sustained receptor blockade and good antitumor efficacy.
Frank Hilberg, Gerald J Roth, Martin Krssak, Susanna Kautschitsch, Wolfgang Sommergruber, Ulrike Tontsch-Grunt, Pilar Garin-Chesa, Gerd Bader, Andreas Zoephel, Jens Quant,[...]. Cancer Res 2008
707
8

Cyclophosphamide versus placebo in scleroderma lung disease.
Donald P Tashkin, Robert Elashoff, Philip J Clements, Jonathan Goldin, Michael D Roth, Daniel E Furst, Edgar Arriola, Richard Silver, Charlie Strange, Marcy Bolster,[...]. N Engl J Med 2006
976
8


High-dose acetylcysteine in idiopathic pulmonary fibrosis.
Maurits Demedts, Juergen Behr, Roland Buhl, Ulrich Costabel, Richard Dekhuijzen, Henk M Jansen, William MacNee, Michiel Thomeer, Benoit Wallaert, François Laurent,[...]. N Engl J Med 2005
654
7

Drug Treatment of Idiopathic Pulmonary Fibrosis: Systematic Review and Network Meta-Analysis.
William J Canestaro, Sara H Forrester, Ganesh Raghu, Lawrence Ho, Beth E Devine. Chest 2016
107
7

Safety and efficacy of pirfenidone in idiopathic pulmonary fibrosis in clinical practice.
Ryo Okuda, Eri Hagiwara, Tomohisa Baba, Hideya Kitamura, Terufumi Kato, Takashi Ogura. Respir Med 2013
71
9

Long-term safety of pirfenidone: results of the prospective, observational PASSPORT study.
Vincent Cottin, Dirk Koschel, Andreas Günther, Carlo Albera, Arata Azuma, C Magnus Sköld, Sara Tomassetti, Philip Hormel, John L Stauffer, Indiana Strombom,[...]. ERJ Open Res 2018
47
14

Pirfenidone treatment in idiopathic pulmonary fibrosis: nationwide Danish results.
Goran Nadir Salih, Saher Burhan Shaker, Helle Dall Madsen, Elisabeth Bendstrup. Eur Clin Respir J 2016
19
36

Real World Experiences: Pirfenidone and Nintedanib are Effective and Well Tolerated Treatments for Idiopathic Pulmonary Fibrosis.
Gareth Hughes, Hannah Toellner, Helen Morris, Colm Leonard, Nazia Chaudhuri. J Clin Med 2016
97
7

Effect of continued treatment with pirfenidone following clinically meaningful declines in forced vital capacity: analysis of data from three phase 3 trials in patients with idiopathic pulmonary fibrosis.
Steven D Nathan, Carlo Albera, Williamson Z Bradford, Ulrich Costabel, Roland M du Bois, Elizabeth A Fagan, Robert S Fishman, Ian Glaspole, Marilyn K Glassberg, Kenneth F Glasscock,[...]. Thorax 2016
102
7

Nintedanib in patients with idiopathic pulmonary fibrosis: Combined evidence from the TOMORROW and INPULSIS(®) trials.
Luca Richeldi, Vincent Cottin, Roland M du Bois, Moisés Selman, Toshio Kimura, Zelie Bailes, Rozsa Schlenker-Herceg, Susanne Stowasser, Kevin K Brown. Respir Med 2016
225
7


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.